CARCINOGENS AND CARCINOGENESIS: MOLECULAR MECHANISMS, RISK FACTORS, AND CONTEMPORARY THERAPEUTIC STRATEGIES FOR MALIGNANT NEOPLASMS
- Authors
-
-
Umida Rakhmatulloevna Narzulaeva
PhD Department of Preclinical Sciences, Asia International University
Author
-
Erbol Imongalievich Islomov
Fourth-Year Medical Student, Faculty of General Medicine, Asia International University
Author
-
- Keywords:
- Carcinogenesis; Carcinogens; Malignant Neoplasms; Oncogenes; Tumor Suppressor Genes; TP53; DNA Damage; Cell Immortalization; Angiogenesis; Immunotherapy; Targeted Therapy; CAR-T Cell Therapy; Gene Therapy; Nanomedicine.
- Abstract
-
Cancer remains one of the leading causes of morbidity and mortality worldwide. The development of malignant neoplasms results from complex interactions among environmental carcinogens, genetic susceptibility, epigenetic alterations, and dysregulated cellular signaling pathways.
- References
-
1.Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263.
2.Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31–46.
3.Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.
4.Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
5.World Health Organization. (2024). Cancer. Geneva: World Health Organization.
6.National Cancer Institute. (2024). What is Cancer? Bethesda, MD: National Cancer Institute.
7.Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013). Cancer genome landscapes. Science, 339(6127), 1546–1558.
8.Vogelstein, B., Lane, D., & Levine, A. J. (2000). Surfing the p53 network. Nature, 408, 307–310.
9.Levine, A. J. (2020). p53: 800 million years of evolution and 40 years of discovery. Nature Reviews Cancer, 20, 471–480.
10.Vousden, K. H., & Prives, C. (2009). Blinded by the light: The growing complexity of p53. Cell, 137(3), 413–431.
11.Weinberg, R. A. (2024). The Biology of Cancer (3rd ed.). New York, NY: W. W. Norton & Company.
12.Kumar, V., Abbas, A. K., & Aster, J. C. (2024). Robbins & Cotran Pathologic Basis of Disease (11th ed.). Elsevier.
13.DeVita, V. T., Lawrence, T. S., & Rosenberg, S. A. (2023). DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology (12th ed.). Wolters Kluwer.
14.June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), 1361–1365.
15.Rosenberg, S. A., & Restifo, N. P. (2015). Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 348(6230), 62–68.
- Downloads
- Published
- 2026-07-09
- Issue
- Vol. 2 No. 6 (2026)
- Section
- Articles
- License
-
This work is licensed under a Creative Commons Attribution 4.0 International License.
